Last updated: February 13, 2026
Overview
NDC 00310-7580 is marketed as Sabril (vigabatrin), an anticonvulsant used primarily for infantile spasms and refractory complex partial seizures. The drug is marketed by Lundbeck and has a detailed regulatory history, including approved indications and pricing. Assessing current market dynamics and future pricing trends requires analysis of regulatory status, competitive landscape, demand factors, and reimbursement protocols.
Regulatory and Market Position
- Approval Status: Approved by the FDA for infantile spasms and refractory partial seizures [1].
- Market Exclusivity: Patent protection remained until 2024, with some formulations losing exclusivity recently, exposing the drug to generics.
- Current US Market: Limited to specialized epilepsy clinics, with off-label use in certain neuropsychiatric conditions.
- Global Market: Available in Europe and other markets, but with variability in indications and pricing.
Market Size and Demand Drivers
- Incidence of Target Conditions: Infantile spasms occur in approximately 1 in 2,000 to 1 in 4,000 live births [2].
- Patient Population Estimate (US): Around 250-500 infants diagnosed annually.
- Demand Factors: Efficacy in infantile spasms, safety profile limitations (notably irreversible vision loss), and alternative therapies influence prescribing patterns.
- Reimbursement: Covered mainly through specialty pharmacies and insurance, with high patient cost-sharing.
Competitive Landscape
- Generics Entry: Since patent expiry, multiple generic versions have entered the market, exerting downward pressure on price.
- Alternatives:
- Acthar Gel (repository corticotropin)
- Topiramate, Felbamate, Steroids for infantile spasms.
- Innovative Therapies: New anticonvulsants and gene therapies are in development but not yet replacing gabapentin for infantile spasms.
Pricing Analysis
- Brand Name Price (Pre-Generic):
- In 2021, the retail price for a 60-count, 250 mg capsules ranged around $12,000–$15,000 per month.
- Post-Patent Expiry:
- Entry of generics reduced prices by roughly 40-60%.
- As of 2023, the average wholesale acquisition cost (WAC) for generics varies from $4,500 to $8,000 per month.
- Reimbursement Trends:
- Insurance reimbursement rates mirror reduced pricing, with some patients facing high copays due to formulary restrictions.
Price Projection (Next 3-5 Years)
| Year |
Price Range (Monthly, USD) |
Key Drivers |
| 2023 |
$4,500 – $8,000 |
Continued generic competition |
| 2024 |
$4,000 – $7,500 |
Patent expiration effects stabilize |
| 2025 |
$3,500 – $6,500 |
Market saturation, biosimilar entry |
| 2026 |
$3,000 – $6,000 |
Alternative therapies gaining ground |
Factors influencing prices:
- Increased utilization due to expanding indication approvals.
- Potential regulatory changes aiming to restrict expensive off-label use.
- Entry of biosimilars or new branded therapies for refractory epilepsy.
Regulatory and Policy Impact
- The FDA's REMS (Risk Evaluation and Mitigation Strategy) program restricts access due to vision loss risk, affecting market dynamics.
- Payer policies favor cost-effective generics, further reducing branded drug profitability.
Summary of Key Market Trends
- Significant price reduction since patent expiry.
- Anticipated stabilization as generic market matures.
- Modest growth driven by niche use cases.
- Volume growth constrained by safety concerns and competition.
Key Takeaways
- The US market for vigabatrin has transitioned from high-cost brand pricing to a generic-dominated market, with prices declining sharply.
- Future prices are expected to stay within the current generic range, with slight fluctuations based on market competition and regulatory developments.
- Demand is limited to niche patient populations, restricting volume growth but supporting stable revenues for generic producers.
- Market entry barriers for new products are high due to safety concerns and existing clinical practice patterns.
FAQs
1. How does patent expiry impact vigabatrin pricing?
Patent expiry led to multiple generic entries, reducing prices by up to 60% and shifting market share from the brand to generics.
2. What factors could increase vigabatrin's price in the future?
Introduction of new, safer formulations or approved indications, regulatory changes easing access restrictions, or shortages in generic supply could raise prices.
3. How does the safety profile influence current market dynamics?
The risk of irreversible vision loss restricts off-label use expansion and limits broader market penetration.
4. Are there any key competitors or alternative therapies?
Yes. Drugs such as topiramate and corticosteroids serve as alternatives, but none directly replace vigabatrin for infantile spasms.
5. What is the outlook on regulatory changes affecting price?
Ongoing safety monitoring and potential restrictions may continue influencing market access and pricing, especially if new safety concerns emerge.
References
- FDA. Sabril (vigabatrin) prescribing information. 2021.
- Gilliam, J.C. et al. Incidence and Etiology of Infantile Spasms. Epilepsia. 2019; 60(11): 2451–2457.
